Sales growth was on the softer side in Q3 although it was hurt by certain order phasing (was 5% q/q organic growth excl. this). The CEO commented that September was strong and the trajectory continued in October. The key, we think, is to achieve a steep acceleration in sales given that the company will double the US sales force by 2026E as well as continuing to expand the clinical evidence to further strengthen its long-term growth prospects.
LÄS MER
